Antibiotics and Immunotherapy: Too Much of Anything is Bad!

Eur Urol. 2020 Oct;78(4):544-545. doi: 10.1016/j.eururo.2020.07.027. Epub 2020 Aug 15.

Authors

Vancheswaran Gopalakrishnan¹, Bret R Sellman², Taylor S Cohen², Phillip A Dennis³

Affiliations

¹ Microbiome Discovery, Microbial Sciences, BioPharmaceuticals R & D, AstraZeneca, Gaithersburg, USA. Electronic address: vancheswaran.gopalakrishnan@astrazeneca.com.
² Microbiome Discovery, Microbial Sciences, BioPharmaceuticals R & D, AstraZeneca, Gaithersburg, USA.
³ Oncology R & D, AstraZeneca, Gaithersburg, USA.

PMID: 32811714
DOI: 10.1016/j.eururo.2020.07.027

No abstract available

Publication types

Editorial
Comment

MeSH terms

Anti-Bacterial Agents* / adverse effects
Antibodies, Monoclonal, Humanized*
Humans
Immunologic Factors
Immunotherapy / adverse effects

Substances

Anti-Bacterial Agents
Antibodies, Monoclonal, Humanized
Immunologic Factors
atezolizumab